ARK Genomic Revolution ETF (ARKG) Rises +12% in 30 Days on Genomics Momentum
Key Takeaways
- ARKG gained roughly +12% over the trailing 30 days, extending a broader multi-month rebound in genomics and healthcare-innovation equities.
- Over the last quarter, the fund climbed approximately +26%, reflecting renewed demand for high-growth biotechnology and precision-medicine names.
- The advance was concentrated in core positions spanning gene editing, DNA sequencing, molecular diagnostics, and AI-driven drug discovery.
- ARKG is actively managed and non-diversified, with heavy exposure to small- and mid-cap stocks, making it highly sensitive to shifts in risk appetite and interest-rate expectations.
Understanding ARKG's Focus and Key Holdings
The ARK Genomic Revolution ETF is an actively managed, non-diversified exchange-traded fund that seeks long-term growth of capital. It invests primarily (at least 80% of assets) in domestic and foreign equity securities of companies relevant to the genomics revolution, including businesses focused on gene editing, sequencing, synthetic biology, molecular diagnostics, and AI-enabled drug discovery. The strategy is thematic and actively managed rather than index-linked, and it carries a net expense ratio of 0.75%.
The portfolio typically holds roughly 30 stocks, with healthcare representing essentially the entire equity allocation. The largest positions have recently included Twist Bioscience (TWST), 10x Genomics (TXG), Tempus AI (TEM), CRISPR Therapeutics (CRSP), Personalis (PSNL), Guardant Health (GH), Absci (ABSI), Natera (NTRA), Illumina (ILMN), and CareDx (CDNA). Because a meaningful share of assets sits in small- and mid-cap, pre-profit companies, the fund's concentration and growth tilt amplify both upside momentum and downside volatility. I also checked this using Tickeron’s AI Screener to see how the holdings compare to others in the industry.
Recent Performance: 30 Days Versus the Quarter
Over the trailing 30 days, ARKG advanced from roughly $47.64 to about $53.35, a gain of approximately +12%. The move was not linear: the fund staged a sharp leg higher in the second half of August, consolidated near the low-to-mid $46 range in early September, and then resumed its climb in the back half of September. This pattern is characteristic of a trend-driven but volatile advance rather than a steady, range-bound grind.
The broader three-month picture is stronger still. From a level near $42 at the end of June, ARKG rose to about $53.35, a quarterly gain of roughly +26%. The fund initially pulled back into the mid-$37 area during July before recovering into August, underscoring the high-beta, momentum-sensitive nature of its underlying holdings. From what I see, this volatility is typical for a fund with this kind of exposure.
Drivers Behind the 30-Day Rally
The recent 30-day rally was propelled by a broad rotation back into high-growth healthcare and biotechnology equities. ARKG's most influential holdings—companies in DNA sequencing, gene editing, liquid biopsy, and AI-accelerated drug development—led the advance, and the fund's concentrated structure allowed a handful of outperformers to drive a disproportionate share of the move.
Several thematic currents supported sentiment. Continued progress in AI-powered biology and drug discovery benefited positions such as Tempus AI and Recursion Pharmaceuticals (RXRX), while sequencing and diagnostics names including Illumina, Natera, and Guardant Health rallied alongside improving demand expectations for genomic testing. Gene-editing developers such as CRISPR Therapeutics, Intellia Therapeutics (NTLA), and Beam Therapeutics (BEAM) also contributed amid renewed optimism around clinical pipelines.
Macroeconomic conditions reinforced the move. A more favorable interest-rate backdrop and firmer investor appetite for long-duration, growth-oriented assets tend to lift the early-stage biotechnology companies that dominate this portfolio. Because many ARKG holdings have earnings concentrated far in the future, their valuations are especially sensitive to changes in discount rates and overall risk sentiment.
Factors Behind the Quarterly Advance
The roughly +26% advance over the last quarter reflects a longer-running recovery in the genomics and precision-medicine complex after a mid-year lull. The quarter began with a July pullback in speculative growth names before a sustained rebound took hold, suggesting a genuine rotation into innovation-driven healthcare rather than a short-lived bounce.
Structural drivers underpinned the trend. Sequencing cost declines and expanding clinical adoption of genomic and liquid-biopsy testing continued to broaden the addressable market for diagnostics leaders. Meanwhile, the convergence of machine learning and biology kept AI-native drug-discovery platforms in focus. Institutional ETF flows and improving investor sentiment toward biotechnology also helped sustain the rally, while the fund's non-diversified, small-cap-heavy profile amplified returns during the upswing.
ARKG Outlook: Factors to Monitor
Several factors are likely to shape ARKG over the coming months. Interest-rate expectations and the broader appetite for long-duration growth assets will remain a key swing factor, given the fund's tilt toward pre-profit and early-stage biotechnology companies. Inflation trends and the pace of monetary-policy adjustment will therefore matter as much as company-specific developments.
Investors should monitor the earnings and guidance of the fund's largest diagnostics and sequencing holdings, as well as clinical and regulatory milestones across gene-editing and precision-medicine names. Capital flows into thematic and innovation-oriented ETFs, along with funding conditions for early-stage biotech, could also influence both valuations and sentiment. Finally, the concentrated, non-diversified structure of ARKG means that idiosyncratic moves in a few top positions can meaningfully drive returns in either direction, a risk worth weighing alongside the fund's longer-term genomics investment theme. I'm watching this closely as rate decisions unfold.
Using Tickeron’s AI Screener for Stock Research
In my own analysis, I often rely on Tickeron’s AI Screener to scan for individual stocks and ETFs that align with themes like genomics. It applies technical indicators, fundamentals, volatility metrics, price patterns, industry filters, AI-generated signals, and performance data to surface relevant names more efficiently than manual reviews. This has helped me identify breakout candidates and compare holdings within the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
Aroon Indicator for ARKG shows an upward move is likely
ARKG's Aroon Indicator triggered a bullish signal on September 23, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 213 similar instances where the Aroon Indicator showed a similar pattern. In 195 of the 213 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +6.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARKG advanced for three days, in 242 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
The 10-day RSI Indicator for ARKG moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 30 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 75 of 79 cases where ARKG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on October 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARKG as a result. In 81 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ARKG turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 50 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARKG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ARKG broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Category Health
Advertisement